Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Identification and Characterization of Synthetic Viability with ERCC1 Deficiency in Response to Interstrand Crosslinks in Lung Cancer.

Heyza JR, Lei W, Watza D, Zhang H, Chen W, Back JB, Schwartz AG, Bepler G, Patrick SM.

Clin Cancer Res. 2019 Apr 15;25(8):2523-2536. doi: 10.1158/1078-0432.CCR-18-3094. Epub 2018 Dec 11.

PMID:
30538112
2.

Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.

Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.

Nutrients. 2018 Nov 3;10(11). pii: E1644. doi: 10.3390/nu10111644.

3.

Gap Junction Intercellular Communication Positively Regulates Cisplatin Toxicity by Inducing DNA Damage through Bystander Signaling.

Arora S, Heyza JR, Chalfin EC, Ruch RJ, Patrick SM.

Cancers (Basel). 2018 Oct 2;10(10). pii: E368. doi: 10.3390/cancers10100368.

4.

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.

Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072.

5.

Pathomimetic cancer avatars for live-cell imaging of protease activity.

Ji K, Heyza J, Cavallo-Medved D, Sloane BF.

Biochimie. 2016 Mar;122:68-76. doi: 10.1016/j.biochi.2015.09.015. Epub 2015 Sep 12. Review.

Supplemental Content

Support Center